Centre for Advanced Neurological Research

June 1982-May1985	:	Completed postgraduate training in Internal Medicine during which period taught Clinical Medicine to undergraduates.
January 1986-December 1988	:	Completed Post-Doctoral Fellowship (DM) in Neurology during which period actively participated in teaching undergraduates, postgraduates in Medicine, Psychiatry and Paediatrics.
April 1990-January 1995	:	Worked as Assistant Professor in Neurology. During this period has organized and actively participated in teaching undergraduate and post-graduates in Medicine, Paediatrics and Psychiatry. Actively involved in the training programme for DM post-graduates and was in charge of organizing and implementing the teaching programs. Also conducted bedside teaching, delivered lectures and moderated seminars, journal clubs and other academic activities. Responsibilities included the task of setting entrance examination question papers for selection of DM postgraduates.
January 1995 -1998	:	Working as Associate Professor in Neurology,Kasturba Medical College, Manipal and Mangalore, India. Was responsible for setting up the neurology intensive care unit at University Medical centre( the superspeciality hospital of Kasturba Medical College, Mangalore). In addition to routine academic work, was also a guide for MD Medicine postgraduates.
June 2000 –December 2015	:	Working as Professor of Medicine (Neurology), involved in teaching final year medical undergraduates and post graduates in Medicine, Pediatrics & Psychiatry.
April 2007- Present	:	Director, Center for Advanced neurological research. This center which was set up with modest philanthropic donations in 2007, is the first and only clinician driven basic science center at Nitte (Deemed to be University). It grew in stature from a modest PCR laboratory to a research facility with capability for real time PCR work, cell culture and bioassay and Flowcytometry. It is a recognized center for the awarding of PhD in Biosciences.
January 2016 onwards	:	Professor and Head, Department of Neurology, KS Hegde Medical Academy, Nitte (Deemed to be University).
August 2018 - January 2019	:	Visiting Professor, Department of Neurology, Harvard medical School (Brigham and Women's Hospital)
February 2019 onward	:	Professor of Neurology & Director of Center for Advanced Neurological Research

Research Training and Experience

1. Research Fellowship in the United Kingdom- (1995-1997). Worked as Research Fellow in Clinical Neurology (Demyelinating disorders) at Royal Victoria Infirmary, Newcastle and Research Associate at the University of Newcastle, United Kingdom. Worked on the following projects (see publications)
   
   
   1. Evaluation of the effect of I.V. Methyl prednisolone on the Cytokine Profile (tumour necrosis factor – alpha) and soluble adhesion molecules (VCAM I and ICAM I) in Multiple Sclerosis.
   
   
   2. Assessment of disability in Multiple sclerosis-a clinical and radiological study.
   
   
   3. Research associate and local (Newcastle) treating physician for the following trials
   
   
   
   
   1. Double-blind randomised multicentre European trails on Beta-Interferon Ia (Serono REBIF), Beta Interferon Ib (Schering)
   
   
   2. Double-blind randomised multicentre European trails on Beta Interferon Ia rn (Avonex) studies in Multiple sclerosis
   
   
   3. Phase II Double blind placebo controlled study of clinical effects of   Lexipafant (British Biotech) in patients with multiple sclerosis.
   
   
2. Research Associate –Department of Molecular and Fisheries Microbiology, College of Fisheries, University of Agricultural Sciences, Mangalore, Karnataka. (2000- 2003). Worked on the following projects (See publications)
   
   
   1. Evaluation of the use of universal primers – (16s rRNA) in the diagnosis of Culture negative meningitis.
   
   
   2. Use of seminested PCR strategy in the diagnosis of culture negative meningitis
   3. Diagnostic utility of Methylation PCR in the evaluation of fragile X Mental retardation.
   
   
   4. Molecular diagnosis of Campylobacter jejuni infection in Guillain Barre Syndrome.
   
   
3. Research training in Multiple sclerosis Genetics – University of Cambridge (December 2009-2010 April). Worked as the Jaquelline Du Pre awardee of 2009-2010 in The Department of Neurology, Addenbrookes Hospital, Cambridge, UK.

My academic interests are focused on central nervous system demyelinating disorders and in particular Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). Since 2007 I have established a registry for demyelinating CNS disorders at my university, in the southwest part of India at Mangalore. This registry has patients from around 300 sq. kilometer radius and beyond and is one of the few dedicated to the study and care of patients suffering from demyelinating disorders in India. In the past decade, we have studied the clinical and demographic features of these disorders, conducted longitudinal follow-up studies, and published the first population-based prevalence study in our country. Simultaneously we have, based on our experiences, established cost-effective treatment algorithms for the management of patients in resource-poor settings which have now become standard of care in our part of the world. I have additionally special interest in the characterization of optic neuritis, particularly in the detection of clinically silent disease using optical coherence tomography and specialized electro retinography. 

Alongside clinical work, I have researched and published my work on the genetic susceptibility for MS and NMOSD in the south Indian population. Our studies support the notion that ethnicity may not be a significant contributing factor that influences genetic susceptibility for these diseases. My lab is currently funded for developing novel diagnostic biomarkers and animal models for studying NMOSD. rnMy responsibilities have additionally included teaching of medical undergraduates, post graduates in Internal medicine, Psychiatry, and Pediatrics and providing guidance for Ph.D. students in my lab.

1. The National Academy of sciences, India (NASI) fellowship (Government of India)-2022


2. Secretary , Pan Asian committee for treatment and research in MS (PACTRIMS), 2022-present


3. Nominated Member of the International Panel for classification of Myelin Oligodendrocyte Glycoprotein Antibody Diseases (MOGAD).


4. Visiting Professor, Department of Neurology, Harvard medical School (Brigham and Women's Hospital) - August 2018- January 2019.


5. Fulbright-Nehru Scholar (Academic & Professional Excellence)-2018.


6. Nominated as member/ Chairperson of the Institutional ethics committee of Sree Chitra Tirunal Institute for Medical Sciences & Technology - 2017- 2018.


7. Nominated Member, Central Organizing Committee of Pan Asian committee for treatment and research in Multiple sclerosis ( PACTRIMS) - 2015 - present


8. Nominated member of International Medical Consortium- Guthy Jackson Neuromyelitis optica (NMO) foundation, USA-2013- present


9. Member of the advisory group, World atlas of Multiple sclerosis, 2nd edition, Multiple Sclerosis International federation (MSIF) - 2012 -2013.


10. National Convenor, Indian Academy of Neurology- subsection on Autoimmune CNS disorders - 2013-present


11. India representative at Multiple sclerosis International federation (MSIF) -2009-2011.


12. India representative at Asia Pacific Expert committee on Multiple sclerosis (APEC) - 2011-2013


13. Member, Academic Council, Nitte (Deemed to be University), Karnataka, India-2011-2013


14. Best researcher and Investigator award for work on "Genetic susceptibility for Multiple sclerosis in Indian population" by Pan Asian Committee for treatment and Research in Multiple sclerosis [PACTRIMS] -2010.


15. Jaquelline du Pre Grant from Multiple sclerosis International federation, United Kingdom - 2010-2011.


16. Rhodes Scholar Mridula Shastri memorial fellowship -1995.


17. Visiting Professor, Department of Neurology, Harvard medical School (Brigham and Women's Hospital) - August 2018- January 2019.
18. Fulbright-Nehru Scholar (Academic & Professional Excellence)-2018.
19. Nominated as member/ Chairperson of the Institutional ethics committee of Sree Chitra Tirunal Institute for Medical Sciences & Technology - 2017- 2018.
20. Nominated Member, Central Organizing Committee of  Pan Asian committee for treatment and research in Multiple sclerosis ( PACTRIMS) - 2015 - present 
21. Nominated member of International Medical Consortium- Guthy Jackson Neuromyelitis optica (NMO) foundation, USA-2013- present 
22. Member of the advisory group, World atlas of Multiple sclerosis, 2nd edition, Multiple Sclerosis International federation (MSIF) - 2012 -2013.
23. National Convenor, Indian Academy of Neurology- subsection on Autoimmune CNS disorders - 2013- 2017.
24. India representative at Multiple sclerosis International federation (MSIF) -2009-2011.
25. India representative at Asia Pacific Expert committee on Multiple sclerosis (APEC) - 2011-2013
26. Best researcher and Investigator award for work on "Genetic susceptibility for Multiple sclerosis in Indian population" by Pan Asian Committee for treatment and Research in Multiple sclerosis [PACTRIMS] -2010.
27. Jaquelline du Pre Grant from Multiple sclerosis International federation, United Kingdom - 2010-2011.
28. Rhodes Scholar Mridula Shastri memorial fellowship -1995.
    

Undergraduate and post graduate teaching and guideship for PhD students

List of Membership in Academic Bodies

• Permanent member, Neurological Society of India


• Permanent member, Indian Academy of Neurology


• Life Member, Multiple Sclerosis Society of India


• Member, National Medical Panel for Multiple sclerosis


• Member, International medical and scientific board of Multiple sclerosis International Federation (MSIF)


• Life member, Indian Society of Human Genetics

List of Professional reviews

• Multiple Sclerosis and related disorders
• Multiple sclerosis Journal
• Multiple Sclerosis Clinical Experimental & Translational
• Journal of Neurological sciences
• BMC Neurology
• Journal of Neurology, Neurosurgery, Psychiatry
• Frontiers Neurology
• Editorial board member of Neuroimmunology journal

List of National reviews

• Neurology India
• Annals of Indian Academy of Neurology
• Indian Journal of medical research

1. Volpe G, Jerkute N,Girafa G, Motamedi S, Zimmerman H, Bereuster C , Pandit L ,DCunha A, et al Inter eye difference metrics on OCT for Myelin oligodendrocyte protein antibody associated optic neuritis. Neurol Neuroimmunol Neuroinflamm 2024;11:e200291.


2. Arnett S, Chew SH, Leitner U, et al. Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis. J Neurol .2024; https://doi.org/10.1007/s00415-024-12452-8


3. Pandit L, Mustafa S, Sudhir A, Malapur P, D'Cunha A. Determining Effectiveness of "Off‑Label Therapies" for Multiple Sclerosis in a Real‑World Setting.. Ann Indian Acad Neurol. 2024;1;27(3):250-253. doi: 10.4103/aian.aian_114_24. Epub 2024 Jun 24.


4. Oertel FC, Zimmermann HG, Motamedi S, Bereuter C, Manthey LM, Ashtari F, Kafieh,R , Dehghani A, Pourazizi M, Pandit L et al. Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders. Neurol Neuroimmunol Neuroinflamm 2024;11:e200273


5. The IMSRN collaborators. The Indian multiple sclerosis and allied demyelinating disorders registry and research network (IMSRN): Inception to reality. MSARD. Multiple Sclerosis and Related Disorders 2024; 87: 105627.


6. Hjerthen I,  Hacker CT ,  Pandit L et al. Underemployment, work hour reduction, and income loss: A global, multi-centered, cohort study of neuromyelitis optica. J Neurol Science.2023; 455:121066.


7. Sasitorn S, Pandit L, Matteo M. Editorial: MOGAD current knowledge and future trend. Front Neurol 2023; DOI 10.3389/fneur.2023.1283217.


8. Pandit L, D'Cunha A, Malli C, Sudhir A. Comparison of live and fixed cell- based assay performance - Implications in the diagnosis of MOGAD in a low- middle income country. Front Immunol. DOI; 10.3389/fimmu.2023.1252650


9. Malli C, Pandit L, D'Cunha A, Sudhir A. Helicobacter pylori infection may influence prevalence and disease course in myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD) similar to MS but not AQP4-IgG associated NMOSD. Front Immunol. 2023; 14:1162248. doi: 10.3389/fimmu.2023.1162248. 


10. Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, Cree BAC, De Sèze J, Fujihara K, Kim HJ, Hornby R, Huda S, Kissani N, Kleiter I, Kuwabara S, Lana-Peixoto M, Law L, Leite MI, Pandit L, Pittock SJ, Quan C, Ramanathan S, Rotstein D, Saiz A, Sato DK, Vaknin-Dembinsky A. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023;10(4):e200124. doi: 10.1212/NXI.0000000000200124.


11. Asseyer S, Asgari N, Bennett J, Bialer O,Blanco Y, Bosello F, Camos-Carreras A,Carnero Contentti E, Carta S, Chen J, Chien C,Chomba M, Dale RC, Dalmau J, Feldmann K,Flanagan EP, Froment Tilikete C,Garcia-Alfonso C, Havla J, Hellmann M, Kim HJ,Klyscz P, Konietschke F, La Morgia C,Lana-Peixoto M, Leite MI, Levin N, Levy M,Llufriu S, Lopez P, Lotan I, Lugaresi A,Marignier R, Mariotto S, Mollan SP, Ocampo C,Cosima Oertel F, Olszewska M, Palace J, Pandit L, Peralta Uribe JL, Pittock S, Ramanathan S, Rattanathamsakul N, Saiz A, Samadzadeh S, Sanchez-Dalmau B, Saylor D, Scheel M, Schmitz-Hübsch T, Shifa J, Siritho S,Sperber PS, Subramanian PS, Tiosano A, Vaknin-Dembinsky A, Mejia Vergara AJ,Wilf-Yarkoni A, Zarco LA, Zimmermann HG,Paul F and Stiebel-Kalish H. The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicentre study on diagnosis and treatment of acute optic neuritis. Front. Neurol. 2023;14:1102353. doi.org/10.3389/fneur.2023.1102353.
12. Oertel FC, Zimmermann HG, Motamedi S, Chien C, Aktas O, Albrecht P, Ringelstein M, Dcunha A, Pandit L, Martinez-Lapiscina EH, Sanchez-Dalmau B, Villoslada P, Palace J, Roca-Fernández A, Leite MI, Sharma SM, Leocani L, Pisa M, Radaelli M, Lana-Peixoto MA, Fontenelle MA, Havla J, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Marignier R, Cobo-Calvo A, Asgari N, Jacob A, Huda S, Mao-Draayer Y, Green AJ, Kenney R, Yeaman MR, Smith TJ, Cook L, Brandt AU, Paul F, Petzold A. Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2023 Feb 21:jnnp-2022-330608. doi: 10.1136/jnnp-2022-330608.
13. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Jan 24:S1474-4422(22)00431-8. doi: 10.1016/S1474-4422(22)00431-8. PMID: 36706773.
14. Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, Behbehani R, Berger T, Bikbov MM, Biotti D, Biousse V, Boschi A, Brazdil M, Brezhnev A, Calabresi PA, Cordonnier M, Costello F, Cruz FM, Cunha LP, Daoudi S, Deschamps R, de Seze J, Diem R, Etemadifar M, Flores-Rivera J, Fonseca P, Frederiksen J, Frohman E, Frohman T, Tilikete CF, Fujihara K, Gálvez A, Gouider R, Gracia F, Grigoriadis N, Guajardo JM, Habek M, Hawlina M, Martínez-Lapiscina EH, Hooker J, Hor JY, Howlett W, Huang-Link Y, Idrissova Z, Illes Z, Jancic J, Jindahra P, Karussis D, Kerty E, Kim HJ, Lagrèze W, Leocani L, Levin N, Liskova P, Liu Y, Maiga Y, Marignier R, McGuigan C, Meira D, Merle H, Monteiro MLR, Moodley A, Moura F, Muñoz S, Mustafa S, Nakashima I, Noval S, Oehninger C, Ogun O, Omoti A, Pandit L, Paul F, etal. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022:S1474-4422(22)00200-9.
15. Pandit L, D'Cunha A, UM Puneeth. Incidence and Prevalence of Neuromyelitis Optica Spectrum Disorders in the background of International Consensus Diagnostic Criteria . A Systematic Review. Neurol India 2022 70;1771-79
16. Pandit L, Sudhir A,Malli C, D'Cunha A. COVID-19 infection and vaccination against COVID-19: Impact on managing demyelinating CNS disorders in Southern India- experience from a demyelinating disease registry.Mult Scler Relat Disord 2022; 66:104033.
17. Oertel FC, Sotirchos ES, Zimmermann HG, Motamedi S, Specovius S, Asseyer ES, Chien C, Cook L, Vasileiou E, Filippatou A, Calabresi PA, Saidha S, Pandit L, D'Cunha A, Outteryck O, Zéphir H, Pittock S, Flanagan EP, Bhatti MT, Rommer PS, Bsteh G, Zrzavy T, Kuempfel T, Aktas O, Ringelstein M, Albrecht P, Ayzenberg I, Pakeerathan T, Knier B, Aly L, Asgari N, Soelberg K, Marignier R, Tilikete CF, Calvo AC, Villoslada P, Sanchez-Dalmau B, Martinez-Lapiscina EH, Llufriu S, Green AJ, Yeaman MR, Smith TJ, Brandt AU, Chen J, Paul F, Havla J; with the GJCF International Clinical Consortium for NMOSD and the CROCTINO study group. Longitudinal retinal changes in MOGAD. Ann Neurol. 2022 ; 92: 476- 485.
18. Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, Gouider R, Hacohen Y, Hellwig K, Hemmer B, Kappos L, Ladeira F, Lebrun-Frénay C, Louapre C, Magyari M, Mehling M, Oreja-Guevara C, Pandit L, Papeix C, Piehl F, Portaccio E, Ruiz-Camps I, Selmaj K, Simpson-Yap S, Siva A et al. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Mult Scler. 2022; 28:1424-56.
19. Lu A, Zimmermann HG, Specovius S, Motamedi S, Chien C, Bereuter C, Lana-Peixoto MA, Fontenelle MA, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, D'Cunha A, Kim HJ, Hyun JW, Jung SK, Leocani L, Pisa M, Radaelli M, Siritho S, May EF, Tongco C, De Sèze J, Senger T, Palace J, Roca-Fernández A, Leite MI, Sharma SM, Stiebel-Kalish H, Asgari N, Soelberg KK, Martinez-Lapiscina EH, Havla J, Mao-Draayer Y, Rimler Z, Reid A, Marignier R, Cobo-Calvo A, Altintas A, Tanriverdi U, Yildirim R, Aktas O, Ringelstein M, Albrecht P, Tavares IM, Bichuetti DB, Jacob A, Huda S, Soto de Castillo I, Petzold A, Green AJ, Yeaman MR, Smith TJ, Cook L, Paul F, Brandt AU, Oertel FC; GJCF International Clinical Consortium for NMOSD. Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2022; 93: 188- 195.
20. Oertel FC, Specovius S, Zimmermann HG, Chien C, Motamedi S, Bereuter C, Cook L, Lana Peixoto MA, Fontanelle MA, Kim HJ, Hyun JW, Palace J, Roca-Fernandez A, Leite MI, Sharma S, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, D'Cunha A, Aktas O, Ringelstein M, Albrecht P, May E, Tongco C, Leocani L, Pisa M, Radaelli M, Martinez-Lapiscina EH, Stiebel-Kalish H, Siritho S, de Seze J, Senger T, Havla J, Marignier R, Calvo AC, Bichuetti D, Tavares IM, Asgari N, Soelberg K, Altintas A, Yildirim R, Tanriverdi U, Jacob A, Huda S, Rimler Z, Reid A, Mao-Draayer Y, Soto de Castillo I, Petzold A, Green AJ, Yeaman MR, Smith T, Brandt AU, Paul F. Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1068
21. Pandit L, Malli C, D'Cunha A, Sudhir A. Overcoming the challenges in diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay . J Neuroimmunol 2021; 360:577706.
22. Pandit L. Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines. Mult Scler 2021; 27: 1320-1322
23. Malli C, Pandit L, , D'Cunha A, Sudhir A . Coexistence of autoantibodies and other autoimmune diseases with Multiple Sclerosis and relatedrndisorders - Experience from the Mangalore Demyelinating Disease Registry (MANDDIR). Ann Indian Acad Neurol 2021 24:740-744..
24. Pandit L, Malli C, D'Cunha A, Sudhir A. Role of Viral Infections in Multiple Sclerosis pathogenesis among Indian Population. Neurol India2021;69:681-5.
25. Soares-dos-Reis R , Li Tsz-Ching J , Kim S H, et al.T he Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence, Mult Scler Relat Disord 2021, doi: https://doi.org/10.1016/j.msard.2021.103080
26. Pandit L, Mustafa S. Epidemiology and clinical features of demyelinating disorders in India.Neurology and Clinical Neuroscience 2021: https://doi.org/10.1111/ncn3.12488
27. D'Cunha A, Pandit L, Malli C, Sudhir A. Evaluating the role of HLA DRB1 alleles and oligoclonal bands in influencing clinical course of Multiple Sclerosis- A study from the Mangalore demyelinating disease registry . Ann Indian Acad Neurol 2021: 24(3):356-360.
28. Pandit L, Cox LM, Malli C, D'Cunha A, Rooney T, Lokhande H, Willocq V, Saxena S, & Chitnis T. Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4. Neurol Neuroimmunol Neuroinflamm. 2020; 8(1):e907.
29. Specovius S, Zimmermann HG, Oertel FC Chien C, Bereuter C, Cook L J, Lana Peixoto M A, Fontenelle M A, Kim H J, Hyun J W, Jung S K, Palace J, Fernandez A R, Diaz A R, Leite M I, Sharma S M, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, D'cunha A et al Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO) . BMJ Open 2020; 10:e035397.
30. Whittam D H, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O,   Hacohen Y, Pandit L et al. Treatment of MOG antibody associated disorders: results of an international survey. J neurol2020; doi: 10.1007/s00415-020-10026-y.
31. Tenembaum S, Yeh EA and the Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Front. Pediatr 2020; 25;8:339..
32. Hor J Y, Asgari N, Nakashima I, Broadley S A, Leite M I, Kissani N, Jacob A, Marignier R, Weinshenker B G, Paul F, Pittock S J, Palace J, Wingerchuk DM, Behne JM, Yeaman M R and Fujihara K on behalf of the Guthy-Jackson Charitable Foundation International Clinical Consortium for NMOSD. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front. Neurol 2020,26;11:501
33. Whittam D H, Cobo-Calvo A, Lopez-Chiriboga A S, Pardo S, Gornall M, Cicconi S, Brandt , Berek K, Berger T, Jelcic I, Gombolay G, Pandit L et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord 2020; 44:102251.
34. Bhatia R, Padma Srivastava M V, Khurana D, Pandit L, Mathew T, Gupta S, Netravathi M, Nair SS, Singh G ,Singhal BS. Consensus Statement on Immune Modulation in Multiple Sclerosis and Related Disorders during the COVID‑19 Pandemic: Expert Group on Behalf of the Indian Academy of Neurology. Ann Ind Acad Neurol 2020;23:5-14
35. Cook L J, Rose J W, Alvey J S, Jolle A M, Kuhn R, Yeaman M R on behalf of The Guthy-Jackson Charitable Foundation International Clinical Consortium (GJCF-ICC).Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD.Neurol Neuroimmunol Neuroinflamm 2019;6 (5): e583.
36. Pandit L. No evidence of disease activity (NEDA) in multiple sclerosis - Shifting the goal posts .Ann Ind Acad Neurol 2019; 22: 261-263.
37. Pandit L, Mustafa S, Nakashima I et al. MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response Mult Scler J Exp Transl Clin. 2018;4(3) : 1-9. 
38. Pandit L, Mustafa S, Uppoor R et al. Reversible paraspinal muscle hyperintensity in anti-mog antibody-associated transverse myelitis. Neurol Neuroimmunol Neuroinflamm 2018; 5:e412.
39. Pandit L, Nakashima I, Mustafa S et al. Anti Myelin Oligodendrocyte Glycoprotein associated Immunoglobulin G (AntiMOG‑IgG)‑associated Neuromyelitis Optica Spectrum Disorder with Persistent Disease Activity and Residual Cognitive Impairment. Ann Ind Acad Neurol 2017; 20:411-3.
40. Pandit L, Mustafa S. Spontaneous remission lasting more than a decade in untreated aqp4antibody-positive NMOSD. Neurol NeuroimmunolrnNeuroinflamm 2017;4:e351.
41. D'Cunha A, Pandit L, Malli C. Genetic variations in the Dravidian population of South West coast of India: Implications in designing case-control studies. Indian J Med Res 2017;145: 753-757
42. Steinman L, Bar-Or A, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: Part I. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e276. 
43. Bar-Or A, Steinman L, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: Part II. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e277
44. Pandit L, Sato D, Mustafa S et al. Serological markers associated with   NMO spectrum disorders in south India .Ann Indian Acad Neurol 2016;19:505‑509
45. D'Cunha A, Pandit L, Malli C. CD6 gene polymorphism rs17824933 is associated with multiple sclerosis in Indian population. Ann Ind Acad Neurol 2016;19:491‑494
46. Pandit L, Sato D, Mustafa S et al. Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India. Mult Scler J Exp Trans Clinic 2016; 2:1-5.
47. Pandit L, Maria B, Beecham AH et al. European multiple sclerosis risk variants in the south Asian population. Mult Scler 2016; 22(12):1536-1540.
48. Pandit L, Malli C, Singhal B et al. HLA association in South Asian Multiple Sclerosis. Mult Scler 2016;22(1):19-24
49. Juryńczyk M, Weinshenker B, Pandit L et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol. 2016; 263(1):140-9
50. Pandit L. Neuromyelitis optica spectrum disorders-an update. Ann Ind Acad Neurol 2015; 18:S11:15.
51. Weinshenker BG, Barron G, Behne JM, Guthy-Jackson Charitable Foundation International Clinical Consortium. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology2015 28;84(17):1805-15
52. Melamed E, Levy M, Pandit L et al. Update on Biomarkers in Neuromyelitis Optica. Neurol Neuroinflam 2015 23; 2(4):e134.
53. Kim HJ, Paul F, Lana-Peixoto MA, Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015 Mar 17; 84(11):1165-73.
54. Kremer S, Renard F, Achard S , Guthy-Jackson Charitable Foundation NMO International Clinical Consortium. Use of advanced MRI techniques in Neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72(7):815-822.
55. Pandit L, Malli C, D'Cunha A et al. HLA association in Neuromyelitis Optica in Indian population . Mult Scler 2015; 21(9):1217-8.
56. Bennett JL, Seze J de, Peixoto ML, Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository et al.Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler 2015;21(6):678-88.
57. Malli C, Pandit L, D'Cunha A et al. Environmental factors related to Multiple sclerosis in Indian population. 2015 PLoS ONE 10(4): e0124064. 
58. Pandit L, Asgari N, Apiwattanakul M et al. Demographic and Clinical features of Neuromyelitis optica- A review. Mult scler 2015; 21(7):845-53.rn
59. Pandit L, Mustafa S. Mycophenolate in the treatment of Multiple Sclerosis- A preliminary report. Neurol India 2014; 62: 646- 648.
60. . Mustafa S, Pandit L. Approach to diagnosis and management of optic neuropathy. Neurol India 2014; 62: 599- 605.
61. Pandit L, Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India in India. Mult Scler 2014; 20:1651-3.
62. Pandit L,Mustafa S. Optimizing the management of Neuromyelitis Optica and Spectrum disorders in resource poor settings: Experience from the Mangalore demyelinating disease registry. Ann Ind Academy Neurol.2013; 16: 572- 576.
63. Pandit L, Ramagopalan SV, Malli C, D'Cunha A, Kunder R, Shetty R,  Association of vitamin D and multiple sclerosis in India. Mult Scler 2013; 19:1592- 1596.
64. Pandit L, Malli C, D'Cunha A et al. Association of Epstein-Barr virus infection with multiple sclerosis in India. J Neurol Sci 2013;325: 86-89.rn
65. Pandit L, Shetty R, Misri Z et al. Optic neuritis: Experiences from a south Indian demyelinating disease registry. Neurol India 2012; 60: 470-475
66. Pandit L. Insights into the changing perspectives of multiple sclerosis in India. Autoimmune diseases.2011, Doi:10.4061/2011/937586
67. Pandit L, Murthy JMK. Treatment of Multiple Sclerosis. Ann Ind Acad Neurol. 2011;14: 65-69
68. Pandit L, Ban M, Sawcer N et al. Evaluation of the established non-MHC Multiple Sclerosis loci in an Indian Population. Mult Scler 2011; 17:139-143.r
69. Pandit L, Ban M, Sawcer N et al. Genetic risk factors for multiple sclerosis in Indians: Do they differ from western populations? Mult Scler 2010; 16: S1268- S1273
70. Pandit L, Shetty R, Mustafa S et al. Optic spinal MS in India is distinct from NMO - Clinical and HLA class 11 association studies. Mult Scler 2010; 16: S263-S280.
71. Pandit L, Shetty R, Bhat IG et al. Seronegative neuromyelitis spectrum disorders in India. Mult Scler 2009; 5: S15-S269.
72. Pandit L. Mitoxantrone in MS-Invited commentary. Neurol India 2009; 57:424-425.
73. Pandit L. Transverse myelitis spectrum disorders. Neurol India 2009; 57:126-132.
74. Pandit L.. Differential diagnosis of white matter diseases in the tropics. Ann Indian Acad Neurol 2009;12:12-21.rn
75. Pandit L. Neuromyelitis optica antibody (NMO-IgG) status in Indian patients with multiple sclerosis and allied demyelinating disorders. Neurol Asia 2008; rn13 : 175- 178.
76. Pandit L NMO-IgG in Indian patients with Multiple sclerosis & allied idiopathic inflammatory demyelinating disorders of the central nervous system. Mult Scler 2009; 15:131-136.
77. Pandit L, Shetty R, Bhat IG et al .Anti - Aquaporin 4 antibody seropositivity in Multiple Sclerosis and allied demyelinating disorders in Indian patients. Ann Ind Acad Neurol 2008; 11(S2)138-139.
78. Pandit L Multiple sclerosis and allied demyelinating disorders in India. Advances in clinical neurosciences and rehabilitation (ACNR) 2008; 8:30-31.
79. Pandit L, Shetty R, Bhat IG et al. Spectrum of Multiple Sclerosis and related demyelinating disorders in India in the background of revised diagnostic criteria Ann Ind Acad Neurol 2007;10: (S2) 44-45.
80. Pandit L, Pai M, Shankar SK et al. Multifocal tumour like presentation of white matter- a case report. Neurol India. 1998; 46 : S96
81. Pandit L, Beveridge C, Coulthard C et al. Predictors of disability in Multiple sclerosis. Neurol India.1998; 46: S67- 68.
82. Pandit L, Dickenson A, Bates D. Cytokine and Adhesion molecule profile in Multiple Sclerosis patients following Intravenous High dose Methyl Prednisolone. Neurol India. 1997; 45:S66-67.
83. Pandit L, Coulthard C, Bates D. Clinical and Radiological correlation of disability in Multiple Sclerosis. J Neurol Neurosurg Psychiatry1997; 63:262- 272.
84. Pandit L, Rao SN. Multiphasic Disseminated Encephalomyelitis. Neurology India 1998; 46:74-75.
85. Pandit L, Rao S N. Recurrent Myelitis. Journal of Neurology Neurosurgery and Psychiatry 1996; 60: 336-338.
86. Pandit L, Subramania R, Rao S N. Multiple Sclerosis in Costal Karnataka. Neurol India 1993;41: 143-146.rnChapters in Books:
87. Pandit L. Demyelinating disorders of the Central Nervous System. In: Kamath S (ed). API Textbook of Medicine.12th ed. Jaypee Brothers; 2022
88. Pandit L. Women with Central Nervous System Demyelinating Disorders: Special Needs in Pregnancy and Child Birth. In: Clinical Practice of Multiple Sclerosis and Related Disorders. Second Edn. Bhatia R, Srivastava MVP (Eds.). KWX Communications Pvt. Ltd. New Delhi, India. 2022:232-42.rnrn
89. Pandit L. Managing Multiple sclerosis and allied disorders during COVID-19 pandemic. In P N Sylaja (eds). Reviews in Neurology, New Delhi:Wolters Kluwer(India), Indian Academy of Neurology CME Publication; 2021: 49-56
90. Pandit L. Demyelinating disorders of the CNS. In: Kamath S (ed). API textbook of Medicine.11th ed. CBS publishers; 2019
91. Pandit L. Neuromyelitis Optica Spectrum Disorders. In: IAN Textbook of Neurology: Jaypee Brothers; 2018
92. Pandit L. Demyelinating disorders in India-An update In: Wander GS (ed) Medicine Update Mumbai: Jaypee Brothers; 2016.
93. Singhal BS, Pandit L. Multiple sclerosis in the tropics. In: Chopra & Sawhney (eds). Neurology in the tropics.11nd ed. Elsevier Asia.2015
94. Pandit L, Jacob A. Neuromyelitis and spectrum disorders. In: Chopra & Sawhney (eds). Neurology in the tropics.11nd ed. Elsevier Asia ,2015
95. Pandit L, Mustafa S. Optic neuropathy in the India; a brief overview. In: Singh G, Das SK (eds) Reviews in Neurology, New Delhi: Elsevier India;  2014: 24-28.
96. Pandit L. Multiple sclerosis: Treatment options. In: Singh VP, Nair MD (eds). Progress in Clin Neuroscience, Vol. 27. New Delhi: Byword Books; 2013: 62-70.
97. Pandit L. Immunology & Immunogenetics of Multiple sclerosis. In: Taly AB,Singh,G.(eds) Reviews in Neurology . CME program of Indian Academy of Neurology; 2009
98. Agrawal A, Dhaval P, Pandit L. Stroke in Pregnancy in Candolotti JT and Burnside JE ( eds).women and stroke research, Nova Publishers,2008rn
99. Agrawal A, Dhaval P, Pandit L. Tumor and stroke in Candolotti JT and Burnside JE ( eds).women and stroke research, Nova Publishers,2008
100. Agrawal A, Dhaval P, Pandit L. Cerebral venous thrombosis in Candolotti JT and Burnside JE ( eds).women and stroke research, Nova Publishers,2008.
101. Agrawal A, Dhaval P, Pandit L. Stroke in developing countries, in Candolotti JT and Burnside JE ( eds).women and stroke research, Nova Publishers,2008
102. Pandit L. Impact of Molecular Genetics on the diagnosis and management of neurological disorders. In: Radhakrishnan K (ed) Reviews in Indian Neurology 2005, Indian Academy of Neurology CME Publication; 2005: 33-46,
103. Pandit L. Demyelinating disorders of the Central Nervous System with relevance to India. In: Radhakrishnan K (ed) Reviews in Indian Neurology 2004, Indian Academy of Neurology CME Publication;2004: 65-79.
104. Pandit L. The role of PCR in the diagnosis of CNS infections: a developing country perspective. In: Radhakrishnan K (ed) Reviews in Indian Neurology 2003, Indian Academy of Neurology CME Publication;2003: 50-71
105. Pandit L. Immunogenetics in Neurological disorders -An overview. Progress in Clinical Neurosciences 1995; 10: 63-81.rnOther publications:
106. Pandit L. Coexistence of autoimmune diseases and autoantibodies in patients with myasthenia gravis. Neurol India 2016;64:7
107. Raghotham A, Pandit L. Large unruptured proximal (A1) anterior cerebral artery aneurysm with aplasia of the contralateral A1.Neurol India 2014; 62:80- 82.
108. Pandit L, Chickabasaviah Y, Ragotham A et al. Neoplastic Parkinsonism- An illustrative case report . Ann Ind Acad Neurol 2013; 16:441- 443.
109. Pandit L, Yasha M, Anandan N et al. Lymphomatosis cerebri -a rare cause of leucoencephalopathy . J Neurol Sci 2010: 293:122-124.
110. Pandit L, Narayanappa G, Bhat IG et al. Autosomal recessive tubular aggregate myopathy in an Indian family. Eur J Paed Neurol. 2009; 13:373-375
111. Pandit L, Agrawal A, Mudgal S et al. Tuberculous spinal meningitis - a treatable cause of myeloradiculopathy. Infect Dis Clin Pract.2009; 17:281-282.
112. Agrawal A, Joharapurkar SR, Pandit L et al. Infect Disease Clin Pract.2008; 16: 345-348.
113. Agrawal A, Jake T, Pandit L et al. Management of subdural hematoma. Infect Disease Clin Pract.2007; 15:149-153
114. Agrawal A, Pandit L, Bhandary S et al: Diagnostic and therapeutic aspects.. Singapore Med J 2007; 48: e181-185.
115. Agrawal A, Shetty MS, Pandit L et al. Post-traumatic syringomyelia. Ind J Orthop 2007;41:398-400
116. Pandit L, Gayathri N, Shetty L et al. Adult onset Leigh syndrome - a case report. Ann Indian Acad Neurol 2007;10:55-57.
117. Agrawal A, Pandit L, NayakV, et al. Pre-Chiasmatic nerve injury following frontal contusion. Eur J Gen Med 2007;4:45-47.
118. Agrawal A, Timothy J, Pandit L et al. Neurogenic pulmonary odema. Eur J Gen Med. 2007;4 :25-32
119. Pandit L, Agarwal A. Neuromuscular dysfunction in critical illness. Clinical Neurol Neurosurgery. 2006; 108: 621-627.
120. Pandit L, Agrawal A. Cryptococcal meningitis in a non HIV patient. Eur J Gen Med 2006;3:80-82
121. Agrawal A, Pandit L. Hyperdense middle cerebral artery sign. Eur J Gen Med 2006; 3:45-47 .
122. Agarwal A, Timothy J, Pandit L et al. Post traumatic Epilepsy-An over view. Clin Neurol Neurosurg. 2006; 108: 433-9.
123. Pandit L, Kumar S, Karunasagar I et al. Diagnosis of Partially Treated Culture Negative Bacterial Meningitis Using 16S rRNA Universal Primers and Restriction Endonuclease Digestion. J Med Microbiol.2005;54:1-4.
124. Karunasagar A, Pandit L, Kumar S et al I. Use of methylation sensitive PCR in the evaluation of fragile X syndrome . Ind J Med Res 2005; 122: 429-433.
125. Agarwal A, Pandit L, Bhandary S. et al. Extensive subdural empyema, paranasal sinusitis and orbital cellulitis complicating nasal septum surgery in a child: a case report and review of literature. Paed on call http://www.pediatriconcall.com/ fordoctor/ casereports /NasalSeptumSurgery.asp
126. Agarwal A, Pandit L, Dalal M et al. Neurological manifestations of Hansen's disease and their management. Clin Neurol Neurosurg 2005; 107: 445-454.
127. Agrawal A, Pandit L. Aetio-pathology, Diagnosis and Management of chronic neck pain. Orthopedics 2005; 7: 235-241
128. Thomas SV, Sarma PS, Pandit L et al. Epilepsy care in six Indian cities: a multicenter study on management and service. J Neurol Sci 2001; 188: 73-72.
129. Thomas SV, Sarma PS, Pandit L et al.Economic burden of epilepsy in India. Epilepsia 2001; 42:1052-60..
130. Pandit L, Shanker SK, Pandit A. Acute Thyrotoxic Neuropathy -Basedows Paraplegia revisited. J Neurol Sci 1998; 155: 211-214.
131. Pandit L, Unni N, Rao S N. Secondary Hypokalaemic Periodic Paralysis. J Assoc Physician India, 45: 421-423, 1996.
132. Prabhu GGL, Rao MS, Pandit L et al. Minor variant of alstrom syndrome : report of a case presenting with a perinephric abscess. Ind J Urol 1996; 12: 45-48.
133. Pandit L, Rao S N. Thymomatous Myasthenia Gravis. J Assoc Physician India 1995; 43: 543-545.
134. Pandit L, Pandit A, Aggarwal A et al. Mechanism of voiding dysfunction in the immediate Post-Stroke period. Neurol India 1994; 40: 3-5.
135. Pandit L, Rao S N. Computerised Tomography in Tolosa - Hunt Syndrome. Ind J Ophthalmol 1994; 42: 207-209.
136. Pandit L, Kapadia R, Kini P et al. Metachromatic Leukodystrophy presenting with extrapyramidal disturbances. Indian Paediatrics 1994; 31: 690-694.rn
137. Pandit L, Subramania R, Rao S N. Global aphasia without hemiparesis, clinicoradiological study of three cases. Neurol India 1992; 40: 170-181 rnPublications related to Drug Trials
138. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020; 383(6):546-557. rn
139. Fox RJ, Chan A, Gold R et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations. Neurol Clin Pract 2016;6(3):220-229 .
140. Conry JA, Ng YT, Kernitsky L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia 2014;55(4):558-567
141. Calabresi PA, Kieseier BC, Pandit L et al. ADVANCE Study Investigators. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.Lancet Neurol. 2014; 13657-65. 
142. Ng YT, Conry J, Pandit L et al. OV-1004 study investigators Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study.Epilepsy Behav. 2012; 25: 687-94.
143. Gold R, Kappos L, Pandit L et al. DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-10.
144. Abraham WT, Decaux G, Pandit L et al. HARMONY Study Group. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int.2012 ;82:1215- 22
145. Ho TW, Pearlman E, Pandit L et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Rizatriptan Protocol 082 Pediatric Migraine Study Group. Cephalalgia. 2012 ;32: 750-65.
146. Ng YT, Conry JA, Pandit L et al. OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77:1473-81. rnConference proceeding in Pubmed indexed journals 
147. L. Pandit, A. Sudhir, C. Malli, A. D'Cunha. Impact of COVID-19 infection and COVID vaccinations on the management of MS and related disorders in a lowrn middle income country - real world experience from a demyelinating disease registry. Mult Scler J 2022; 28: (3S) 692-945
148. F.C. Oertel, H.G Zimmermann, S. Motamedi,C. Bereuter, C. Chien, O. Aktas, P. Albrecht, M. Ringelstein, A. Dcunha, L. Pandit, E.H Martinez-Lapiscina, B.Sanchez-Dalmau, P. Villoslada et al. Diagnostic value of inter-eye-difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica. Multiple Sclerosis Journal 2022; 28: (3S) 3-129
149. Pandit L, Cox L, Lokhande H, Rooney T, Malli C, D'Cunha A, Willocq V, Saxena S, Chitnis T. Lachnoclostridium species are elevated in aquaporin-4 (AQP4+) rn neuromyelitis optica patients in India and exhibit sequence similarity with AQP4. Mult Scler J 2019; 25: (S2) 224- 225.
150. Soares dos Reis R, Li Tsz-Ching J, Kim H, D'Cunha A, Jacob A, Berthelot E, Pandit L et al. Influence of migration on the prognosis of neuromyelitis optica spectrum disorder in non- Caucasian patients. Mult Scler J 2019; 25: (S2) 138-139.
151. Specovius S, Zimmermann H.G, Chien C, Pandit L et al. The CROCTINO project: an international retrospective multi-center study of retinal optical coherence tomography in 501 patients with neuromyelitis optica spectrum disorders. Mult Scler J 2018;24: (s2) 530-737
152. Pandit L. Autoimmune Encephalitis. Mult Scler J 2018; 368-423.
153. Whittam D, Cobo-Calvo A, Pandit L et al. Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients S13.003. Neurology 2018: 90 (15 Supplement).
154. Huda S, AlOrainy A, Pandit L et al. MRI abnormalities in MOG antibody disease. J Neurol Neurosurg Psychiatry2018: 89;A44-A45.
155. Pandit L, Sato D, Siritho S et al. Characterization of seronegative neuromyelitis optica in 2016. Mult Scler J 2016; 22: (S3) 92.
156. Pandit L. Differentiating Multiple sclerosis from NMOSD in the clinic. Ann Ind Acad Neurol.2016. 19(S)1-132.
157. Pandit L, Sato D, Mustafa S et al. Characterization Of Anti MOG and Anti AQP4 Antibody Associated NMOS in A South Indian Cohort. Mult Scler J 2015; O-2: 21.
158. Pandit L. Management of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders in Resource poor settings. Mult Scler J 2015; L-16: 18.
159. Pandit L, Mustafa S, Malli C et al. Anti MOG antibody associated disease is distinct from Anti AQP4-IgG associated Neuromyelitis Optica rn Spectrum disorders. Ann Ind Acad Neurol 2015; 18: S33-34.
160. Sato DK, Kaneko K, Pandit L et al. Clinical phenotypes of pediatric and adult patients with anti-MOG antibodies. Mult Scler 2015; 21: (S11) 76-653.
161. Pandit L , Malli C, D'Cunha A et al .HLA class II alleles and environmental associations with neuromyelitis optica in Indian population. rn Mult Scler 2014; 20: suppl 285-496.
162. Pandit L. Genetics of multiple sclerosis in Indians. Mult Scler 2014;20: (7) 902
163. Pandit L, Malli C, D'Cunha A et al. Selective association of HLA -DRB1 alleles with Multiple Sclerosis susceptibility in Indian population. Mult rn Scler 2013; 19: (S1) 74-558.
164. Pandit L, Kundapur R. Mangalore model of epidemiological survey-a method for establishing minimal prevalence for demyelinating disorders in resource rn poor countries. Mult Scler J 2013; 19: 644- 702.
165. Pandit L. Genetics of Multiple sclerosis in India . Mult Scler J 2012 18: S515-548.
166. Pandit L, Singhal B, Shetty R et al. Epstein -Barr serology in central nervous system demyelinating disorders from a south Indian disease rn registry. Mult Scler J 2011; 17: S53-S276.
167. Pandit L, Ban M, Sawcer N et al. Genetic risk factors for multiple sclerosis in Indians: Do they differ from western populations? Mult Scler 2010; 16: S1268- rn S1273.
168. Pandit L,Ban M,Sawcer S,et al. .Multiple sclerosis in India:Genetic susceptibility is not different from the west .Ann Ind Acad Neurol 2010; 13:5 supl. 1 (S49)
     

1. Dr Lekha Pandit Spoke at the International Pediatric ECHO MS meeting - an International online teaching platform organized by the MS society of USA. rnTreatment Challenges in Pediatric Multiple Sclerosis- case presentation and discussion. on 26-06-2023.


2. Dr Lekha Pandit was invited to give a lecture on "Management of Pediatric Optic nerve inflammation and the occasion" for the Kakrala Subbha Rao endowment lecture at LV Prasad Institute, Hyderabad on 17th March 2023.


3. Dr Lekha Pandit, Professor of Neurology and Director, Centre for Advanced Neurological Research, Nitte (Deemed to be University) has delivered global health lecture on 30th March 2023 virtually via zoom for faculty, residents, and students of Neurology and Neuroscience at Massachusetts General Hospital/Harvard Medical School, Boston.


4. Dr Lekha Pandit secretary PACTRIMS was invited to speak at PACTRIMS 2022 for "Infection, Immunology and Inflammatory Demyelination: at the Crossroads" session, on the topic titled "Vaccination, MS and immunotherapy - a practical, evidence-based approach"   in Singapore on 24-26 November2022.


5. Dr Lekha Pandit was invited to present a talk on " Diagnosis and treatment of Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)" at the 18th Asian Oceanian Congress of Neurology and 29th Annual conference of the Indian Academy of Neurology (AOCN-IANCON2022) on 4th November 2022 at J W Marriott Hotel Aerocity, New Delhi


6. Dr Lekha Pandit was invited as a panelist for the 2022 GJCF ,Pre-ECTRIMS NMOSD symposium for a session on the topic titled " Addressing Unmet Needs in NMOSD & MOGAD Healthcare-Global Access to Serology & Therapeutics"" at Hilton Amsterdam, Netherlands on 25th October 2022.


7.  Dr Lekha Pandit presented a poster titled "Impact of COVID-19 infection and Covid vaccinations on the management of MS and related disorders in low middle income country-Real world experience from a demyelinating disease registry". At the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022), held in Amsterdam, The Netherlands from 26-28 October 2022
8. Dr Lekha Pandit was invited to attend and present at the international Roundtable Conference on Myelin oligodendrocyte glycoprotein associated disorders (MOGAD) at Boston USA on 29th-30th September 2022.


9. Dr Lekha Pandit took part in the International pediatric ECHO-MS educational program- Part 2 as faculty, conducted virtually on 13/06/2022.


10. Dr Lekha Pandit was invited as faculty for the " World Multiple Sclerosis Day" Public Education Program conducted by Indian Academy of Neurology on 30th May 2022.


11. Dr Lekha Pandit delivered a lecture on "Differentiating MS from other white matter diseases- A practical Approach" in 6th annual conference of Telangana Neurosciences society TNSCON-2022 . Held on 5th, 6th March 2022 at Warangal, Telangana state.


12. Dr Lekha Pandit delivered a lecture on "Diagnosis and management of demyelinating CNS disorders - a case based approach" on the web series of Neuro Master's Classs Season -3 for DM/DNB students held on 7th February from 7.00 to 9.00 PM.


13. Dr Lekha Pandit participated as a HUB Team Faculty Member for the International Pediatric ECHO MS Program on 01-02-2022 Dr. Pandit worked with fellow ECHO HUB team members and co-directors to design a well-rounded and interactive curriculum and facilitated a 90-minute session on the topic of "Pediatric-Onset Multiple Sclerosis". This is a partnered CME initiative between the International Pediatric Multiple Sclerosis Study Group (IPMSSG) and the National Multiple Sclerosis Society (NMSS) designed to foster global collaboration and increase pediatric MS and related demyelinating disease expertise through sharing evidence-based best practices, contemporary research, and patient cases.


14. Dr Lekha Pandit delivered an invited lecture titled "Serological diagnosis of NMOSD and MOGAD: Practical considerations and limitations" at IAN CON 2021 held in Hybrid mode on 14-11-2021.


15. Dr Lekha Pandit was invited to speak at the 13th Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) Congress 2021 program on "The Gut environmental factors and MS and NMO" which was held in digital mode from 26th to 28th November 2021.


16. Dr Lekha Pandit was invited to give a lecture on "Management of Pediatric Optic nerve inflammation and the occasion" for the Kakrala Subbha Rao endowment lecture at LV Prasad Institute, Hyderabad on 17th March 2023.


17. Dr Lekha Pandit secretory PACTRIMS was invited to speak at PACTRIMS 2022 for "Infection, Immunology and Inflammatory Demyelination: at the Crossroads" session, on the topic titled "Vaccination, MS and immunotherapy - a practical, evidence-based approach" in Singapore on 24-26 November.


18. Dr Lekha Pandit presented a poster titled "Impact of COVID-19 infection and Covid vaccinations on the management of MS and related disorders in low middle income country-Real world experience from a demyelinating disease registry". at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022), held in Amsterdam, The Netherlands from 26-28 October 2022


19. Dr Lekha Pandit was invited as a panelist for the 2022 GJCF Pre-ECTRIMS NMOSD symposium for a session on the topic titled " Addressing Unmet Needs in NMOSD & MOGAD Healthcare-Global Access to Serology & Therapeutics"" at Hilton Amsterdam, Netherlands on 25th October 2022


20. Dr Lekha Pandit, Professor of Neurology and Director, Centre for Advanced Neurological Research, Nitte (Deemed to be University) has been awarded the prestigious fellowship of the National Academy of Sciences India(NASI) for her pioneering work involving Neurology/Neuroimmunology.


21. Dr Lekha Pandit took part in the International pediatric ECHO-MS educational program- Part 2 as faculty, conducted virtually on 13/06/2022


22. Dr Lekha Pandit was invited as faculty for the " World Multiple Sclerosis Day" Public Education Program conducted by Indian Academy of Neurology on 30th May 2022


23. Dr Lekha Pandit was invited as a faculty for the " World Multiple Sclerosis Day" public education program conducted by Indian Academy of Neurology on 30th May 2022 web link https://www.youtube.com/watch?v=GeAp5vApS44


24. Dr Lekha Pandit is invited as a co-editor in the journal Frontiers in Neurology (IF 4.003, Cite Score 4.0) on the topic research on Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD),Current Knowledge and Future Trends


25. Dr Lekha Pandit delivered a lecture on "Differentiating MS from other white matter diseases- A practical Approach" in 6th annual conference of Telangana Neurosciences society TNSCON-2022 . Held on 5th, 6th March 2022 at Warangal, Telangana state.


26. Dr Lekha Pandit delivered a lecture on "Diagnosis and management of demyelinating CNS disorders - a case based approach" on the web series of Neuro Master's Classs Season -3 for DM/DNB students held on 7th February 2022 from 7.00 to 9.00 PM.


27. Dr Lekha Pandit, participated as a HUB Team Faculty Member for the International Pediatric ECHO MS Program on 01-02-2022. Dr. Pandit worked with fellow ECHO HUB team members and co-directors to design a well-rounded and interactive curriculum and facilitate a 90-minute session on the topic of "Pediatric-Onset Multiple Sclerosis". This is a partnered CME initiative between the International Pediatric Multiple Sclerosis Study Group (IPMSSG) and the National Multiple Sclerosis Society (NMSS) designed to foster global collaboration and increase pediatric MS and related demyelinating disease expertise through sharing evidence-based best practices, contemporary research, and patient cases.


28. Dr Lekha Pandit delivered an invited lecture titled "Serological diagnosis of NMOSD and MOGAD: Practical considerations and limitations" at IAN CON 2021 held in Hybrid mode on 14-11-2021.


29. Dr Lekha Pandit was invited to speak at the 13th Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) Congress 2021 program on "The Gut environmental factors and MS and NMO" which was held in digital mode from 26th to 28th November 2021.


30. Dr Lekha Pandit was invited to speak at the 8th European committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Focused Workshop 2021 on "The Risk of Infections for MS Disease Modifying Treatments (DMTs)" which was held fully digital on 14 and 21 April 2021


31. Dr Lekha Pandit was invited as speaker on A WEBINAR ON MULTIPLE SCLEROSIS-PANEL DISCUSSION. A public awareness and education programme and advice by experts on different aspects of multiple sclerosis conducted by Indian Academy of Neurology on WORLD BRAIN DAY on 22-07-2021.


32. An online interview was conducted with Dr Lekha Pandit, on promotion of World Brain day by World Federation of Neurology (WFN), addressing management of Multiple Sclerosis in resource poor settings on 10-06-2021.


33. Dr Lekha Pandit, was invited as speaker at" Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) inaugural educational webinar PACTMAN series 01 " held Virtual on 29-04-2021.


34. Dr Lekha Pandit was invited to speak at the 8th European committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Focused Workshop 2021 on "The Risk of Infections for MS Disease Modifying Treatments (DMTs)" which was held fully digital on 14 and 21 April 2021.


35. The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) has initiated a collaborative effort to update recommendations for clinical approaches to the differential diagnosis of MS.On behalf of the steering committee of the international MS Differential Diagnosis Consortium, Dr Lekha Pandit is invited to participate in the working group to produce a paper for the topic titled " Differential Diagnosis Considerations in Non-Western Geographic Regions".


36. Dr Lekha Pandit delivered an online lecture titled "Autologous hematopoietic stem cell transplant (aHSCT) as standard of care in multiple sclerosis- Not enough evidence for such recommendation" in VIRTUAL AGRIM NEUROLOGY UPDATE (VANU) 2020 on 16th October 2020.


37. Invited online lecture by Dr Lekha Pandit on "Bio-markers interpretation in Demyelinating Disease and Overview of Sero-Negative NMOSD" conducted by Bangur Institute of Neurosciences Demyelination Clinic PDT CME on 1st October 2020.


38. Dr Lekha Pandit delivered a lecture on the topic titled "Management of Multiple Sclerosis" conducted by Bangur Institute of Neurosciences Demyelination Clinic PDT CME on 8th October 2020.


39. Dr Lekha Pandit spoke on management of multiple sclerosis and related disorders during the Covid Pandemic -National Webinar organised Intas Biopharmaceuticals on 28th April 2020.


40. Pandit L was invited to speak on ""Risk of Infections in MS DMTs", at the 8th ECTRIMS on 12-13 March 2020 in Tel Aviv, Israel.


41. Task Force meeting on "National Multiple Sclerosis and Allied Demyelinating Disorders Registry and Research Network of India. Pandit L -Running a registry and optimising data collection at National institute of medical statistics, ICMR, New Delhi. 23.10.2019.


42. Pandit L - Treatment challenges in MOG-IgG disease, in the plenary session of the first congress of Sri Lanka committee for  Treatment and Research in Multiple sclerosis and related disorders, at Colombo.
43. Pandit L -Gut Microbiome in Autoimmune CNS disorders among Indian population - at the Annual conference of the Indian Academy of Neurology, at Hyderabad, India on 4th October, 2019.


44. Pandit L presented a poster at the 35th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the 24th Annual conference of Rehabilitation in MS (RIMS), titled " Lachnoclostridium species are elevated in Aquaporin-4 IgG+ Neuromyelitis Optica Spectrum Disorders in India and exhibit sequence similarity with AQP4" (11-13 September 2019 Stockholm, Sweden) .


45. Pandit L was invited as the Multiple Sclerosis expert from Asia Pacific region for the meeting of the International Working Group on Access to treatment (IWGA) for Multiple Sclerosis (11-12th July 2019, London)


46. Pandit L was an invited principal speaker and chairperson for Neuro Immunology session at 1st East Zone Neuro PDT CME 2019 (May 2019, Kolkata).


47. Pandit L. Demyelinating CNS Disorders in women with emphasis on MS and NMO. Invited speaker at Women In Neurology- New & Emerging Research Symposium (March 2018, Udaipur).


48. Pandit L was invited to attend and present in the Guthy -Jackson Charitable foundation 's Annual NMO Roundtable Conference March 2018


49. Pandit L. Autoimmune Encephalitis. Invited speaker at the 10th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) in November 2017 at Ho Chi Minh City, Vietnam.


50. Pandit L was invited to attend and present in the Guthy -Jackson Charitable foundation 's Annual NMO Roundtable Conference 2017 from, March 12th to14th 2017


51. Pandit L. Differentiating Multiple Sclerosis from NMOSD in the clinic. Invited speaker at IANCON, Kolkata November 2016


52. Pandit L. Characterization of seronegative neuromyelitis optica in 2016. Paper presented at ECTRIMS, United Kingdom September 2016,


53. Pandit L. Different approaches in diverse clinical settings in Multiple sclerosis management - 'Ideal' vs practical realities of 'Real world'. Talk delivered at MS Expert meeting (Biogen), Athens, Greece, May 2016.


54. Pandit L was invited to attend the Guthy -Jackson Charitable foundation 's Annual NMO Roundtable Conference 2016 from February29-March 1,2016


55. Pandit L. Demyelinating disorders in India- an over view- Invited lecture at national meeting of Association of Physicians of India (APICON), Hyderabad, January 2016.


56. Pandit L. Role of Biomarkers in the diagnosis and management of optic neuritis. Invited speaker at Synapse 2016,Shankar Nethralaya, Chennai , January2016.


57. Pandit L, Sato D, Mustafa S et al. Characterization Of Anti MOG and Anti AQP4 Antibody Associated NMOSD in South India. Paper presented at PACTRIMS, Seoul, Korea, November 2015.


58. Pandit L. Management of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders in Resource Poor Settings. Invited speaker at PACTRIMS, Seoul, Korea, November 2015.


59. Pandit L, Mustafa S, Malli C et al. Anti MOG antibody associated disease is distinct from Anti AQP4-IgG associated Neuromyelitis Optica Spectrum disorders . Paper presented at IANCON 2015,Agra.


60. Pandit L. Gene environmental interactions in Neuromyelitis optica. Invited speaker at the plenary session of Guthy Jackson Foundation International symposium, Los Angeles, USA, March 2015


61. Pandit L Challenges in the diagnosis and management of neuromyelitis optica spectrum disorders. Invited speaker at Karnataka association of neurology annual meeting, February 2015, Mangalore.


62. Pandit L , Malli C, D'Cunha A et al .HLA class II alleles and environmental associations with neuromyelitis optica in Indian population.ECTRIMS 2014 in Boston, Massachusetts, USA.


63. Pandit L: Invited speaker at panel discussion on treatment choices for Multiple Sclerosis in India. Annual conference of Indian Academy of Neurology, Chandigarh, November 2014.


64. Pandit L. Delivered keynote address on "The end points in MS disease evaluation: Clinical disability vs. relapse rate vs. Imaging" at NEUCON-Controversies in Neurology, Hyderabad 2014.


65. Pandit L. Multiple sclerosis therapeutics- Invited speaker at Dr Balaparameshwara symposium on therapeutic advances in Neuroimmunology, at Andrapradesh Neurological Society Conference, Tirupathi, June, 2014.


66. Pandit L, Malli C, D'Cunha A et al. Selective association of HLA -DRB1 alleles with Multiple Sclerosis susceptibility in Indian population. Paper presented at ECTRIMS, Copenhagen (October 2013).


67. Pandit L. Genetics of multiple sclerosis in Indians. Invited speaker at the plenary session of PACTRIMS, Kyoto, Japan (November 2013).


68. Pandit L. Neuromyelitis spectrum disorders in India. Invited speaker at the roundtable conference of the Guthy Jackson foundation, Los Angeles, California, USA (November 2013).


69. Pandit L. Neuromyelitis spectrum disorders. Invited speaker at Tropicon 2013, Tropical neurology Subsection of Indian Academy of Neurology, Guwahati, Assam (February 2013).


70. Pandit L. Treatment options In Multiple Sclerosis. Invited speaker at the Continuing medical association program, Annual meeting of Neurological society of India, New Delhi(December 2012)


71. Pandit L, Malli C, Shetty R et al. Environmental factors associated with Multiple Sclerosis. Invited talk at annual meeting of association of Sri Lankan neurologist, Colombo, SriLanka (November 2012).


72. Thompson AJ, Browne P, Taylor B, Battaglia M, Pandit L, Tremlett H, Uitdehaag B, Holloway E. MSIF Atlas of MS Database update: Multiple sclerosis resources in the world 2013. Paper presented at ECTRIMS, Lyon, France (October 2012).


73. Pandit L, Kundapur R. Mangalore model of epidemiological survey-a method for establishing minimal prevalence for demyelinating disorders in resource poor countries. Paper presented at PACTRIMS2012, Beijing, China (September 2012).


74. Pandit L, Shetty R, Singhal B et al. Environ mental factors associated with Multiple scleropsis in India. Are they different from the west?Paper presented at annual conference of Indian Academy of Neurology (September 2012, Ahmadebad).


75. Pandit L. Treatment practices for Multiple sclerosis in India. Invited speaker at Asia pacific expert committee (APEC) meeting, Hongkong, July 2012.


76. . Pandit L. Differential diagnosis of white matter diseases. Invited lecture, Kannur Neuro Club, April2012, Kerala.


77. Pandit L, Singhal B, Shetty R et al. Epstein -Barr serology in central nervous system demyelinating disorders from a south Indian disease registry. Poster presented at ECTRIMS (Sept 2011).


78. Pandit L. Genetics of Multiple sclerosis in India. Invited presentation at the plenary session of PACTRIMS 2011 (Singapore, June 2011)


79. Pandit L. Oral medications for Multiple sclerosis. Invited speaker at the national meeting on controversies in neurology Neucon2011 (Mumbai, June 2011)


80. Pandit L. Insights into MS in India. Invited speaker at the annual meeting of Kerala Association of neurologists (May2011, Wyanad, Kerala).


81. Pandit L, Ban M, Stephen Sawcer et al. Genetic risk factors for Multiple Sclerosis in Indians-Do they differ from western population? PACTRIMS, 2010.

Neurology

Teaching of medical undergraduates, post graduates in Internal medicine ,Psychiatry and Pediatrics and providing guidance for PhD students in my lab

Research Grants Title	Funding Agency	Amount
Identifying and characterizing Aquaporin -4 specific T cells in Neuromyelitis optica spectrum disorders	Nitte (Deemed to be University) 2020-2021	Rs 1,99,948
Development of a sensitive cell based assay for the detection of a diagnostic biomarker (Myelin oligodendrocyte glycoprotein antibody) in Neuromyelitis optica spectrum disorders	ICMRrn(2020-2023)	Rs 30,72,528
Indian Multiple Sclerosis and Allied Demyelinating Disorders Registry and Research Network	ICMR (2020-2025)	Rs 32,29,000
Use of Wistar rat brain sections in Immunohistochemistry studies for characterization of seronegative Neuromyelitis optica spectrum disorders-A pilot study	Nitte (Deemed to be University) 2019-2020	Rs 1,40,000
Evaluation of AQP4-IgG administration with human complement for developing Neuromyelitis optica spectrum disorder (NMOSD) rodent mouse model - A pilot study	Nitte (Deemed to be University) 2019-2020	Rs 1,25,000
"Development of a cost effective cell based assay for the diagnosis of Neuromyelitis optica spectrum disorders in India"	DBT-BIRAC (2019-2021)	Rs 40,93,000
Neuromyelitis optica Biomarker assay development - Phase1 (Culture & Maintenance of Human Embryonic Kidney cell lines for development of cell based biomarker assay for sensitive diagnosis of Neuromyelitis optica spectrum disorders.)	Nitte University  (2015-2016)	Rs1,20,000
Understanding the role of herpes viruses and human endogenous retrovirus in MS pathogenesis	Dept of Biotechnology  (2014-2017)	Rs 65,00,000
Environmental & genetic risk factors for MS in Indian population	Dept of Science & Technology, Govt of India (2011-2014)	Rs 58,01,282
Study of European risk variants in MS in Indian population	MS society of Great Britain (2013-2014)	Rs 15,00,000
Association of H pylori with NMO and NMO spectrum disorders among Indian population	Nitte University (2014-2015)	Rs1,33,900
Association of HLA Class I (A&C) Alleles in Multiple Sclerosis among Indian population- a pilot study	Nitte University  (2013-2014)	Rs 2,05,375
Study of patterns and prevalence of demyelinating disorders in urban Mangalore	Indian council of medical research (2010-2013)	Rs 35,80,000
Evaluation of Anti Aquaporin Antibody in Indan Demyelinating disorders (collaboration with Professor Weinshenker, Mayoclinic, Minnesotta, USA)	Intramural funding (2007-2008)	Rs 1,00,000
A longitudinal study to determine the clinical and radiological predictors for ADEM and MS and to evaluate underlying genetic susceptibility.	Indian council of Medical research (2007-2010)	Rs 12,50,000
Molecular genetics & genetic epi demiology of some common triplet repeat disorders in Coastal Karnataka	Dept.of Science & Technology, (DST,Govt of India)  (2006-2009)	Rs 19,00,000
Molecular Characterization of Campylo- bacter jejuni infection associated with Guillane -Barre syndrome	Life Science research Board (DRDO,Govt of India )  (2005-2007)	Rs10,80,000
Evaluation of Fragile X syndrome as cause of mental retardation	Indian council of medical of research (ICMR) & Nitte Educational Trust (2002-2003)	Rs 25, 000
Use of universal primers in the diagnosis Of culture negative meningitis Use of semi nested PCR in diagnosis of Culture negative meningitis	Rhodes Scholar Mridula Shastri memorial post-doctoral scholarship (2001-2002)	Rs 1,00,000